Formulation Development Outsourcing Market Report by Service, Formulation, Therapeutic Area, End Use, Countries and Companies Analysis 2026-2034

Formulation Development Outsourcing Market Size and Forecast 2026-2034

Formulation Development Outsourcing Market is expected to reach US$ 69.64 Billion by 2034 from US$ 36.14 Billion in 2025, with a CAGR of 7.56% from 2026 to 2034. The formulation development outsourcing market is growing due to increasing pharmaceutical research activities, rising demand for specialized formulation expertise, expanding biologics pipelines, and the need to reduce development costs and timelines while improving efficiency, scalability, regulatory compliance, and speed-to-market for innovative therapies.

Formulation Development Outsourcing Industry Overview

Formulation development outsourcing is the process through which pharmaceutical, biotechnology, and healthcare companies engage specialized contract research and manufacturing organizations to develop and optimize drug formulations. These services include preformulation studies, dosage form design, excipient selection, stability testing, process optimization, and regulatory support. Outsourcing enables companies to access advanced scientific expertise, sophisticated analytical technologies, and specialized infrastructure without substantial capital investments. It helps accelerate development timelines, improve product quality, and ensure regulatory compliance. As drug formulations become more complex, particularly for biologics and targeted therapies, outsourcing has become a strategic approach for enhancing development efficiency and commercialization success.

The formulation development outsourcing market is experiencing steady expansion as pharmaceutical and biotechnology companies increasingly rely on external specialists to support complex drug development programs. Growing investments in novel therapeutics, biologics, and personalized medicines are creating demand for advanced formulation expertise. Outsourcing provides access to specialized technologies, experienced scientific teams, and regulatory capabilities while reducing operational costs and infrastructure requirements. Companies are also seeking to accelerate clinical development and product launches through integrated outsourcing partnerships. Rising pressure to improve research productivity, optimize resources, and manage increasingly sophisticated drug pipelines continues to encourage the adoption of formulation development outsourcing services across global healthcare markets.

Recent Developments in Formulation Development Outsourcing Market

• In September 2025, GBI Biomanufacturing partnered with NanoRetinal, Inc. to support the development and manufacturing of NAR-001, an investigational nanoparticle-based therapy targeting inherited retinal disorders. The collaboration reflects the growing demand for outsourcing partners capable of handling advanced therapeutic products and specialized formulation requirements, further supporting market growth.
• Also in September 2025, Strides Pharma Science, through its subsidiary Strides Pharma Global Pte. Limited, entered into a strategic product development agreement with Kenox. The partnership focuses on collaborative product development initiatives aimed at expanding pharmaceutical portfolios and accelerating market access. Such alliances demonstrate the increasing reliance on outsourcing partnerships to enhance innovation, optimize resources, and improve development efficiency across the pharmaceutical industry.
• In April 2024, CoreRx Inc. strengthened its position in the formulation development outsourcing industry through the acquisition of Societal CDMO Inc. in a deal valued at approximately USD 130 million. The acquisition broadened CoreRx's service portfolio by adding expertise in complex small-molecule formulations, clinical manufacturing, and early-stage drug development. Such industry consolidation enhances outsourcing capabilities and provides pharmaceutical companies with greater access to specialized development resources, reducing the need for significant internal investments.
• In July 2023, Aenova Group formed a strategic collaboration with Galvita to advance the development and production of oral dosage formulations. The partnership expanded access to specialized oral drug formulation technologies and manufacturing expertise. By leveraging external partners for formulation optimization, bioavailability improvement, and scale-up activities, pharmaceutical companies can streamline development processes and accelerate product progression toward commercialization.

Growth Drivers for the Formulation Development Outsourcing Market

Expansion of Advanced Formulation Development Capabilities

The continuous expansion of formulation development infrastructure and technical capabilities by contract service providers is a major growth driver for the formulation development outsourcing market. Pharmaceutical and biotechnology companies increasingly seek outsourcing partners that can support complex oral, injectable, and biologic formulations while accelerating clinical development timelines.

For example, in February 2023, Quotient Sciences announced the expansion of its early-phase formulation development capabilities for oral dosage forms at its Nottingham, UK facility. The enhanced services strengthened the site's existing formulation expertise and increased development capacity through the company's Translational Pharmaceutics platform. Such investments improve the ability of outsourcing providers to deliver integrated development solutions from formulation design through clinical manufacturing.

As drug molecules become more complex and development timelines become increasingly compressed, sponsors are favoring outsourcing partners with advanced infrastructure, formulation expertise, and flexible development models. These capabilities reduce development risks, improve efficiency, and support faster progression from laboratory research to clinical studies, thereby driving sustained market growth.

Growing Demand for End-to-End Biopharmaceutical Development Services

The increasing preference for integrated drug development and manufacturing solutions is significantly contributing to market growth. Pharmaceutical companies are seeking outsourcing partners capable of managing multiple stages of development to reduce operational complexity and improve project coordination.

In May 2024, AGC Biologics and BioConnection entered into a partnership to provide end-to-end biopharmaceutical development and manufacturing services. The collaboration combines AGC Biologics' expertise in drug substance development and manufacturing with BioConnection's specialized aseptic filling capabilities for drug products. Such partnerships enable customers to access comprehensive services through a single outsourcing network.

The demand for streamlined development pathways is increasing as biologics, cell therapies, and advanced medicines require sophisticated manufacturing processes and strict regulatory compliance. Integrated service offerings reduce technology transfer challenges, improve communication between development stages, and accelerate commercialization. Consequently, pharmaceutical companies are increasingly adopting outsourcing models that provide complete development solutions, strengthening market expansion worldwide.

Increasing Commercial Manufacturing Requirements for Complex Therapies

The growing commercialization of advanced therapeutics, including antibody-drug conjugates (ADCs), biologics, and targeted medicines, is creating substantial demand for formulation development outsourcing services. As pharmaceutical pipelines shift toward highly specialized therapies, companies require experienced partners with expertise in formulation, filling, manufacturing, and scale-up activities.

A notable example occurred in October 2023 when Lonza announced the extension of its collaboration with a major biopharmaceutical partner for commercial-scale filling of antibody-drug conjugates. The agreement highlights the increasing need for specialized outsourcing services capable of supporting complex products throughout commercial production.

Many pharmaceutical companies lack the infrastructure and technical expertise required for large-scale manufacturing of advanced therapies. Outsourcing providers offer established facilities, regulatory knowledge, and specialized equipment that help reduce investment risks while ensuring product quality. As more innovative therapies progress toward commercialization, demand for outsourced formulation development and manufacturing support is expected to increase significantly.

Challenges in the Formulation Development Outsourcing Market

Regulatory Complexity and Compliance Requirements

One of the primary challenges facing the formulation development outsourcing market is the increasing complexity of global regulatory requirements. Outsourcing providers must comply with varying standards established by regulatory authorities across multiple regions, including requirements for quality control, documentation, validation, and manufacturing practices.

As pharmaceutical products become more sophisticated, regulatory expectations continue to evolve, creating additional compliance burdens. Any failure to meet regulatory standards can lead to project delays, increased costs, product recalls, or approval setbacks. Service providers must therefore invest heavily in quality systems, training programs, and regulatory expertise. These requirements can increase operational expenses and limit the ability of smaller organizations to compete effectively, creating challenges for both outsourcing providers and pharmaceutical sponsors.

Intellectual Property and Data Security Concerns

Protecting intellectual property and confidential research data remains a significant challenge within the formulation development outsourcing industry. Pharmaceutical and biotechnology companies often share proprietary formulations, manufacturing processes, and clinical development information with external partners.

The growing use of digital platforms, cross-border collaborations, and global outsourcing networks increases the risk of data breaches, unauthorized access, and intellectual property disputes. Sponsors may hesitate to outsource highly valuable projects if they perceive potential risks to proprietary information. Consequently, outsourcing providers must maintain robust cybersecurity systems, confidentiality agreements, and data protection frameworks. The need for continuous investment in security infrastructure can increase operational costs and create barriers for smaller service providers seeking to attract high-value pharmaceutical development projects.

United States Formulation Development Outsourcing Market

The United States remains the largest market for formulation development outsourcing, supported by strong pharmaceutical innovation, substantial R&D spending, and a large concentration of biotechnology companies. Demand is increasing as developers pursue biologics, gene therapies, and personalized medicines requiring specialized formulation expertise. In May 2026, Catalent and Elpida Therapeutics partnered for late-phase manufacturing of an AAV9 gene therapy, while Catalent secured exclusive rights to Elpida's AAV programs, expanding its portfolio to more than 80 partnerships. Additionally, in May 2026, GI Partners acquired Charles River Laboratories' CDMO and Cell Solutions businesses to form Rose BioSolutions, an advanced therapy manufacturer generating USD 143 million in 2025 revenue. These developments highlight continued investment in outsourced development and manufacturing capabilities across the U.S. market.

Germany Formulation Development Outsourcing Market

Germany represents a significant European market for formulation development outsourcing due to its strong pharmaceutical manufacturing base, advanced research infrastructure, and supportive innovation ecosystem. Demand is increasing as pharmaceutical companies seek external expertise to accelerate drug development and improve operational efficiency. Germany's emphasis on biotechnology, advanced therapies, and pharmaceutical innovation continues to support outsourcing adoption across development and manufacturing activities. In July 2025, under the "Made For Germany" initiative, 61 companies launched programs aimed at improving Germany's investment climate through digitalization, innovation, and workforce development. The initiative is expected to strengthen industrial competitiveness and encourage greater technology adoption across life sciences sectors. These improvements are likely to enhance collaboration opportunities between pharmaceutical companies and outsourcing service providers operating in Germany.

China Formulation Development Outsourcing Market

China has become a major hub for formulation development outsourcing, supported by a rapidly expanding biopharmaceutical industry, increasing R&D investments, and strong government initiatives promoting pharmaceutical innovation. Global and domestic drug developers are increasingly partnering with Chinese contract development and manufacturing organizations (CDMOs) to access advanced technologies, skilled scientific talent, and cost-efficient development services. The country is also witnessing continuous investments in biologics and complex drug development platforms. In August 2025, WuXi Biologics launched the WuXia293Stable cell line platform, designed to support the development and manufacturing of difficult-to-express molecules. The platform enhances production efficiency and strengthens the company's biologics development capabilities. Such technological advancements are improving China's competitiveness in outsourced formulation development and supporting sustained market growth.

Saudi Arabia Formulation Development Outsourcing Market

Saudi Arabia's formulation development outsourcing market is expanding steadily due to increasing healthcare investments, pharmaceutical localization initiatives, and the government's Vision 2030 strategy. The country is actively developing domestic pharmaceutical manufacturing capabilities to reduce import dependence and strengthen healthcare resilience. Growing collaborations between public and private stakeholders are creating opportunities for contract development and manufacturing service providers. A significant development occurred in June 2023, when the Public Investment Fund (PIF) established Lifera, a commercial-scale pharmaceutical manufacturing and development company focused on strengthening Saudi Arabia's life sciences ecosystem. Lifera supports local production of innovative medicines, biologics, vaccines, and advanced therapies while enhancing supply chain security and pharmaceutical self-sufficiency. Such investments are expected to increase demand for formulation development outsourcing services and attract international pharmaceutical partnerships in the coming years

Formulation Development Market

The formulation development market plays a critical role in the pharmaceutical industry by transforming active pharmaceutical ingredients into safe, effective, and commercially viable drug products. The market encompasses activities such as preformulation studies, dosage form design, excipient selection, process optimization, and stability testing. Growth is driven by increasing pharmaceutical R&D investments, rising demand for biologics and specialty drugs, and the growing complexity of drug delivery systems. Pharmaceutical and biotechnology companies are increasingly seeking advanced formulation solutions to improve bioavailability, patient compliance, and therapeutic outcomes. Technological advancements in drug delivery platforms and the expansion of personalized medicine are further supporting market growth. Additionally, increasing outsourcing activities and regulatory emphasis on product quality continue to create opportunities for formulation development service providers worldwide.

Oral Formulation Development Outsourcing Market

The oral formulation development outsourcing market is experiencing steady growth due to the continued dominance of oral dosage forms in pharmaceutical treatment. Tablets, capsules, powders, and oral liquids remain the preferred drug delivery methods because of their convenience, patient acceptance, and cost-effectiveness. Pharmaceutical companies increasingly outsource oral formulation development to access specialized expertise in solubility enhancement, modified-release technologies, taste masking, and bioavailability optimization. The market is also benefiting from rising demand for complex oral formulations designed for poorly soluble drug candidates. Contract development organizations offer advanced analytical capabilities and formulation technologies that help accelerate development timelines and reduce operational costs. Growing generic drug production, expanding clinical pipelines, and increasing investments in innovative oral therapies are expected to support sustained market expansion in the coming years.

Oncology Formulation Development Outsourcing Market

The oncology formulation development outsourcing market is expanding rapidly due to the increasing global burden of cancer and the growing number of oncology drugs entering development pipelines. Cancer therapies often involve complex molecules, targeted treatments, biologics, antibody-drug conjugates, and personalized medicines that require specialized formulation expertise. Pharmaceutical and biotechnology companies are increasingly outsourcing formulation activities to access advanced technologies, regulatory support, and specialized manufacturing capabilities. Outsourcing partners assist in developing stable, effective, and patient-friendly oncology formulations while helping sponsors accelerate clinical development and commercialization. Rising investments in oncology research, increasing approvals of targeted therapies, and growing demand for precision medicine are key growth factors. As oncology remains one of the largest therapeutic segments in pharmaceutical development, demand for outsourced formulation services is expected to remain strong globally.

Formulation Development Outsourcing Market Segments

Service

• Formulation Development
• Preformulation

Formulation

• Oral
• Injectable
• Others

Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• Hematology
• Respiratory
• Cardiovascular
• Dermatology
• Others

End Use

• Pharmaceutical and Biopharmaceutical Companies
• Government and Academics Institutes
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• SGS S.A.
• Intertek Group plc
• Recipharm
• Lonza
• Charles River Laboratories International, Inc
• Eurofins Scientific SE
• Labcorp
• Thermo Fisher Scientific, Inc.